濮阳东方医院做人流口碑(濮阳东方男科医院割包皮价格公开) (今日更新中)

NEW YORK, Oct. 3 (Xinhua) -- For the 34-year-old Alexis Steinman, Oct. 3 would have been a great day, because her father Ralph Steinman was announced winner of the 2011 Nobel Prize in Physiology or Medicine.But as she talked to Xinhua at the Rockefeller University where his father worked, she said the day was rather "bittersweet"."This is the moment, but my Dad was not here," said Alexis, trying to hold her tears.The Canadian-born cell biologist Ralph Steinman died of pancreatic cancer on Friday at the age of 68, three days before he was announced the joint winner along with Prof. Bruce Beutler and Prof. Jules Hoffman for the Nobel Prize in Physiology or Medicine."We even talked about the Nobel Prize days before his death," Alexis added."We were like 'OK Dad, I know things aren't going well but the Nobel, they are going to announce it next Monday'. And he was like 'I know I have got to hold out for that. They don't give it to you if you have passed away,'" she said."It's really impossible to describe how our family is feeling right now. We're devastated to have lost Ralph,"Steinman' s son Adam Steinman told reporters at the press conference at Rockefeller University. "We're so incredibly proud of Dad for receiving this wonderful honor ... We know he will live on through his scientific contributions," he said.Rockefeller University president Marc Tessier-Lavigne told reporters during Monday's press conference that the university only heard of Steinman's death from the family about half an hour after news of the Nobel prize came out from Sweden."We are all deeply saddened by his death, " said Tessier- Lavigne , adding that Steinman had been treating himself with a groundbreaking therapy based on his research into the body's immune system.He said Steinman's research has laid the foundation for numerous discoveries in the critically important field of immunology, and it has led to innovative new approaches in how people treat cancer, infectious diseases and disorders of the immune system.Steinman's first student and close colleague Michel Nussenzweig told the press conference packed with reporters, students and professors that "one of the interesting things about Ralph and his discovery is that no one believes it for a really long time.""What was amazing about Ralph was that he just knew that, even though nobody else believed it, this was really important, and he persisted, and finally after a very long time, everyone just found out it was true," Nussenzweig said."Ralph worked until last week. His dream was to use his discovery to make vaccines and it is a dream that is pretty close, and we are all continuing to work to make that come true," he added.The Nobel Foundation made a statement after learning Steinman's death, saying that the decision to award the prize to the Canadian scientist would remain unchanged despite his death, and the prize money will be transferred to his estate.

COTABATO, Philippines, Jan. 2 (Xinhua) -- The health authorities declared an outbreak of a deadly rat fever on Monday in the flood-hit areas in the southern Philippines.At least five people were already dead and as many as 200 were diagnosed in the southern city of Cagayan de Oro with leptospirosis, a fatal animal-borne disease that can result in high fever, internal bleeding and organ failure.The latest fatality, an old woman, died late Monday due to complication.Dr. Jaime Bernadas, regional health minister, said they fear the number of patients displaced by typhoon Washi could increase in the coming days.Congressman Rufus Rodriguez has called on people affected by the floods that killed over 1,200 people to avail of the government's vaccination against the deadly disease.The death toll from tropical storm Washi currently stands at 1, 258 people with many still believed missing. Washi brought massive rains, causing flooding in many areas in the Central and Southern Philippines starting last Dec. 16.

VIENNA, Nov. 25 (Xinhua) -- China is to further help the least developed countries (LDCs) in their development effort through zero-tariff treatment and other measures, Yu Jianhua, China's Assistant Commerce Minister said here Friday.Addressing a LDCs Ministerial Meeting in Vienna, Yu said China will focus on six concrete measures to advance the implementation of the Programme of Action (IPoA), adopted by the Fourth United Nations Conference on LDCs in Istanbul in May.First, as announced by Chinese president Hu Jintao during the G20 summit in Cannes, China would, in the context of South-South cooperation, give zero-tariff treatment to 97 percent of the tariff items of exports to China from the LDCs that have diplomatic relations with China.Second, tilt foreign aid further to the LDCs.Third, carry out cooperation in livelihood projects in the LDCs, including hospital, school, domestic water use and clear energy.Fourth, strengthen agricultural cooperation with the LDCs, including the increase of food aid, dispatching agricultural and technical experts.Fifth, strengthen personnel education in the LDCs to build capacity for self-development.Sixth, continuously promote the establishment of economic and trade cooperation zone in the LDCs by Chinese companies.Yu said that debt crisis in some countries, turmoil in financial markets, inflation pressure in emerging countries; extreme weather and recurrent natural disasters have brought enormous harm to the economies of the LDCs.In this situation, the global community should stand united to give more supports to the LDCs, he stressed.For a long time, China has actively supported the LDCs, under the framework of the South-South Cooperation, through economic and technical aids, debt reduction and personnel training and increase of imports from these countries, he said.Meanwhile, Yu praised the unique role of the UN Industrial Development Organization (UNIDO) in implementing the IPoA, helping structural transformation in the LDCs and promoting the sustainable development.He also said that the Chinese government would continue to support the UNIDO and help the LDCs develop their economies in an all-round way.

BEIJING, Dec. 12 (Xinhua) -- A Foreign Ministry spokesman said on Monday that China welcomes the EU's new measures for coping with the European sovereign debt crisis worked out at the recently-concluded EU summit."We hope relevant measures can help stabilize the market, boost confidence in the market, stop the crisis from worsening, promote employment and economic growth, and push forward European integration," Foreign Ministry Spokesman Liu Weimin said at a routine press briefing.Last Friday at the summit in Brussels, EU leaders agreed on establishing a new "fiscal compact" based on inter-governmental treaties rather than the expected EU treaty changes. Britain opted out of the compact.Under the fiscal compact, member states will have to submit their draft budgetary plans to the European Commission, the EU's executive arm.As world's largest economy, the stable and healthy growth of the European Union and the Eurozone will be crucial to maintaining the momentum of recovery in the world economy, Liu said.China will maintain its support for EU integration, and continue to back the EU's efforts in combating the debt crisis in various ways, so as to jointly promote the stability of the international financial market and the recovery and growth of the world economy, he said."We are confident in Europe and the Eurozone, and believe that the EU has the ability and wisdom to resolve the sovereign debt crisis," Liu said.

BEIJING, Oct. 11 (Xinhuanet) -- An experimental drug that can remove amyloid plaques from the brains of Alzheimer's patients is being developed by Swiss Roche Holding AG in a small early-stage study, according to a report published in the Archives of Neurology on Monday.Researchers suspect the build-up of such plaques may be a cause of the memory robbing disease, although that theory has yet to be definitively proved. Gantenerumab, a biotech drug designed to bind to amyloid plaques in the brain and remove them, is being targeted at the early stages of Alzheimer's with the hope it can slow progression of the disease while patients are still able to function.The Phase I study of 16 Alzheimer's patients tested gantenerumab at two doses against a placebo over six months of treatment.The Roche drug led to a dose-dependent reduction of brain amyloid, while amyloid load increased in patients receiving a placebo, the report said.The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of the experimental drug that are well tolerated and safe, the report said.Much larger trials and further study will be needed to fully understand how gantenerumab works and whether it can stave off Alzheimer's, said the report.Roche is approaching the disease far earlier because amyloid accumulates for 15 years before dementi.

来源：资阳报